Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 62, Issue 4, Pages 629-637Publisher
SPRINGER
DOI: 10.1007/s00262-012-1371-9
Keywords
TIM-3; TIM-4; Cancer vaccines; NK cells; CD8(+) T cells; Melanoma
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Takeda Science Foundation
- Sumitomo Foundation and Terumo Life Science Foundation
- National Cancer Center Research and Development Fund
- Grants-in-Aid for Scientific Research [23501283, 23590534, 23130501, 25112701, 25461503, 22240089] Funding Source: KAKEN
Ask authors/readers for more resources
Cancer vaccines have been developed to instruct the endogenous immune responses to autologous tumors and to generate durable clinical responses. However, the therapeutic benefits of cancer vaccines remain insufficient due to the multiple immunosuppressive signals delivered by tumors. Thus, to improve the clinical efficacy of cancer immunotherapy, it is important to develop new modalities to overcome immunosuppressive tumor microenvironments and elicit effective antitumor immune responses. In this study, we show that novel monoclonal antibodies (mAbs) specifically targeting either T cell immunoglobulin mucin protein-3 (TIM-3) or T cell immunoglobulin mucin protein-4 (TIM-4) enhance the therapeutic effects of vaccination against established B16 murine melanomas. This is true for vaccination with irradiated B16 melanoma cells engineered to express the flt3 ligand gene (FVAX). More importantly, combining anti-TIM-3 and anti-TIM-4 mAbs markedly increased vaccine-induced antitumor responses against established B16 melanoma. TIM-3 blockade mainly stimulated antitumor effector activities via natural killer cell-dependent mechanisms, while CD8(+) T cells served as the main effectors induced by anti-TIM-4 mAb. Our findings reveal that therapeutic manipulation of TIM-3 and TIM-4 may provide a novel strategy for improving the clinical efficacy of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available